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Depletion of peroxisome proliferator-activated receptor 
(PPAR) represents one of the keymolecular changes that underlie
transdifferentiation (activation) of hepatic stellate cells in the gen-
esis of liver fibrosis (Miyahara, T., Schrum, L., Rippe, R., Xiong, S.,
Yee, H. F., Jr., Motomura, K., Anania, F. A., Willson, T. M., and
Tsukamoto, H. (2000) J. Biol. Chem. 275, 35715–35722; Hazra, S.,
Xiong, S., Wang, J., Rippe, R. A., Krishna, V., Chatterjee, K., and
Tsukamoto, H. (2004) J. Biol. Chem. 279, 11392–11401). In support
of this notion, ectopic expression of PPAR suppresses hepatic stel-
late cells activation markers, most notably expression of 1(I) pro-
collagen. However, the mechanisms underlying this antifibrotic
effect are largely unknown. The present study utilized deletion-re-
porter gene constructs of proximal 2.2-kb 1(I) procollagen pro-
moter to demonstrate that a region proximal to 133 bp is where
PPAR exerts its inhibitory effect. Within this region, two DNase
footprints with Sp1 and reverse CCAAT box sites exist. NF-I, but
not CCAAT DNA-binding factor/NF-Y, binds to the proximal
CCAAT box in hepatic stellate cells. A mutation of this site almost
completely abrogates the promoter activity. NF-I mildly but inde-
pendently stimulates the promoter activity and synergistically pro-
motes Sp1-induced activity. PPAR inhibits NF-I binding to the
most proximal footprint (97/85 bp) and inhibits its transactiv-
ity. The former effect is mediated by the ability of PPAR to inhibit
p300-facilitated NF-I binding to DNA as demonstrated by chroma-
tin immunoprecipitation assay.
Cirrhosis, the advanced stage of liver fibrosis, is the 12th leading cause
of medial mortality in 2002 with 27,257 annual deaths according to a
report by the Center for Disease Control. This mortality is even higher
among those with productive ages between 45 and 54, ranking it as the
fourth leading cause of death, highlighting medical and socioeconomic
significance of the disease (1). Currently, there is no medical treatment
for the disease other than liver transplantation. Therefore, the under-
standing of cellular andmolecularmechanisms of liver fibrogenesis is of
primary importance for the development of new treatments. The effec-
tor cell type for liver fibrosis is the hepatic stellate cell (HSC).2 HSCs are
liver mesenchymal cells that are believed to function as pericytes for the
liver microcirculatory system called sinusoids. They are located in the
perisinusoidal space, an anatomical area nestled between the nonlumi-
nal surface of the sinusoidal endothelial cell and themicrovilli surface of
the hepatocyte (2). HSCs constitute 7–10% of the liver cell population
and it stores 85% of the body’s total vitamin A content (3, 4). They also
produce and maintain the normal matrix milieu (basement membrane
components) of the perisinusoidal space. In addition, HSC provides
direct and indirect homeostatic control over hepatocytes through com-
munication via gap junctions (5) and the release of soluble factors such
as hepatocyte growth factor (6), epimorphin (7), and pleiotrophin (8).
However, these cells are also responsible for a severalfold increase in the
production of extracellular matrix components in the genesis of liver
fibrosis (4).
Upon fibrogenic stimulation, quiescent HSCs transdifferentiate to
myofibroblastic cells to produce excessive extracellular matrix. This
cellular transition process is characterized by the loss of vitamin A stor-
age; cellular proliferation and migration; acquisition of a myofibroblas-
tic phenotype, such as expression of  smooth muscle actin, induction
of fibrogenic extracellular matrix genes (collagen type I and III), expres-
sion of autocrine cytokines, such as platelet-derived growth factor (9),
transforming growth factor , transforming growth factor  (10–13),
and their receptors; and expression of adhesionmolecules (intercellular
adhesionmolecules); and chemokines (MCP-1, CINC) (14). In search of
the molecular basis of this unique HSC transdifferentiation phenome-
non, we and others recently disclosed that this process is accompanied
by reduced levels of a member of the nuclear hormone receptor family,
peroxisome proliferator-activated receptor  (PPAR) (15, 16). Further,
our subsequent studies demonstrated that this molecular “defect” in
transdifferentiated HSC is part of the loss of adipogenic transcriptional
program required for the maintenance of HSC quiescence (17). In fact,
this loss of the adipogenic program and the transdifferentiation process
are coordinately reversed by ectopic expression of PPAR (18) or sterol
regulatory element-binding protein 1c (17), another key adipogenic
transcription factor.
One of the most pivotal antifibrotic effects of PPAR is its ability to
inhibit type I collagen expression at the level of the transcription (15,
16). Type I collagen makes up 40–50% of the total collagen proteins in
the normal liver and is increased to 60–70% in the cirrhotic liver (3).
Type I collagen is a heterotrimeric protein composed of two 1(I) and
one 2(I) collagen polypeptides encoded by two different genes that are
coordinately up-regulated in liver fibrogenesis (19). Treatment of acti-
vated HSC with a ligand for PPAR (15, 16) or transduction of these
cells with a PPAR plasmid (15, 16) represses basal 1(I) procollagen
promoter activity that is largely dependent on a proximal 2.2-kb
5-flanking region (19, 20). However, the mechanism by which PPAR
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inhibits type I collagen promoter activity is currently unknown. The
present study investigated where in the proximal 2.2 kb 1(I) procolla-
gen promoter PPAR renders its inhibition and how it achieves this
effect. Our results demonstrate that the 5-flanking 1(I) procollagen
promoter proximal to 133 bp is where PPAR renders its inhibitory
effect. This inhibition is mediated by the ability of PPAR to suppress
NF-I binding and transactivity via inhibition of p300-facilitated NF-I
binding.
MATERIALS AND METHODS
HSC Isolation and Cell Culture—HSCs were isolated from normal
male Wistar rats as previously described (21). Briefly, nonparenchymal
cells were isolated via sequential digestion with Pronase and type IV
collagenase, followed by differential low speed centrifugation. A pure
fraction of HSC was isolated by arabinogalactan gradient ultracentrifu-
gation and collecting the cells at the interface between the medium and
a 1.035 density gradient. Cell purity was determined using phase-con-
trast microscopy and UV-excited fluorescence microscopy. Cell viabil-
ity was determined by trypan blue exclusion. Cells were cultured on a
100-mm dish in low glucose Dulbecco’s modified Eagle’s medium sup-
plemented with 10% fetal bovine serum, 100 mg/ml streptomycin,
10,000 units/ml penicillin, and 25 g/ml amphotericin B. Cells were
maintained in the culture medium for 7 days, at which time adenoviral
vectors were added. Spontaneously immortalized, activated HSCs were
established from a rat with cholestatic liver fibrosis and termed as biliary
fibrosis-derived stellate cells (BSCs) (22). These cells have the pheno-
type similar to activated HSC. BSCs were cultured in 10% low glucose
medium and primarily used in transient transfection experiments.
Adenoviral Vector Infection—Full-length PPAR1 cDNA was cloned
from pCMX-PPAR1 into the transfer vector, subsequently allowing
homologous recombination with the pAdEasy-1 adenoviral plasmid
containing a green fluorescent protein (GFP) reporter (Stratagene, La
Jolla, CA) as previously described (18). A control vector containing
cytomegalovirus-driven GFP reporter gene was also constructed. On
the seventh day of primary rat HSC culture, a vector was applied to
HSCs at amultiplicity of infection of 100 to infect and transduce PPAR
or GFP. The following day, themediumwas changed, and the cells were
cultured for an additional four days to observe the effects on HSC as
described (18).
RNA Isolation and Quantitative Real Time PCR—Total RNA was
extracted from isolated HSC transduced with Ad.GFP and Ad.PPAR
using Trizol reagent (Invitrogen). Two nanograms of total RNA was
used in a 20-l reaction with reverse transcriptase for 30 min followed
by 40 cycles of PCR to produce products using TaqMan Gold One Step
PCR Kit (Applied Biosystems, Foster City, CA) and the ABI 7700 SDS
thermocycler (Applied Biosystems). Synthesized cDNA was amplified
using specific primers for 1(I) collagen (5-TCGATTCACCTACAG-
CACGC, 5-CATTAGCATCCGTGGGAACA), glyceraldehyde-3-
phosphate dehydrogenase (5-TGCACCACCAACTGCTTAG, 5-G-
GATGCAGGGATGATGTTC). Probes were 5,6-carboxylfluorescein
amidite labeled at the 5-end and black hole quencher-1 labeled at the
3-end (Biosearch Technologies Inc., Novoato, CA).
Plasmids and Transient Transfection—pCMX and pCMX-PPAR
were gifts from Ron Evans (The Salk Institute, La Jolla, CA). pSG5 and
p300 were gifts from Michael Stallcup (University of Southern Califor-
nia). Mouse collagen promoter deletion constructs were as follows:
pCol2-lucif, pCol3-lucif, pCol6-lucif, pCol7-lucif, and pUC-Cat (220,
133, 120, and 92 bp/115 bp) were used as previously described
(19, 20). pPac, pPac-NF-I and pPac-Sp1were used to assess the effects of
PPAR on NF-I- or Sp1-driven promoter activity. Renilla pRL-TK was
purchased from Promega. Luciferase promoter deletion constructs
were created via restriction enzyme digestion (XbaI and XhoI) of the
pUC-Cat constructs and insertion into the pGL3-luciferase (Promega)
backbone. Briefly, BSC or NIH3T3 cells were seeded in 6- or 24-well
plates and incubated overnight. A collagen promoter construct, an
expression plasmid (pCMX or PPAR), and F2 reagent (Targeting Sys-
tem, San Diego, CA) were mixed and added to serum-free, high glucose
Dulbecco’s modified Eagle’s medium and incubated for 25 min at 37 °C
and then placed onto the cells. Two hours later, the cells were supple-
mented with 10% high glucose Dulbecco’s modified Eagle’s medium.
The following day, the medium was changed, and the cells were incu-
bated for an additional 8 h. The cell lysates were collected using 5
passive lysis buffer (Promega) and dual luciferase assay (Promega) was
performed using a luminometer (E&G Berthold). Mutations of three
nucleotides (TGG to CAA) in the most proximal reverse CCAAT box
was created by site-directed mutagenesis according to the
QuikChangeTM protocol (Stratagene). Primers were designed to intro-
duce 3-nucleotide mutations into the wild type CCAAT of the FP-1
region of the luciferase promoter deletion construct (133 bp/115
bp). The DNA sequence of each construct was verified using an ABI
Prism 377 sequencer (PerkinElmer Life Sciences). The following prim-
ers were used: FP-1-mutant NF-I (forward), 5-gggccaggcagttctgatCA-
Actgggggccgggctgctggctc-3; FP-1-mutant NF-I (reverse), 5-gagccagc-
agcccggcccccagTTGatcagaactgcctggccc-3.
Electrophoretic Mobility Shift Assay—Nuclear proteins were
extracted fromHSC infected with Ad.GFP or Ad.PPAR using Dignam
A and C reagents (23). Extracts (5–10 g) were incubated in a reaction
mixture (20 mM HEPES, pH 7.6, 100 mM MgCl2, 0.2 mM EDTA, 2 mM
dithiothreitol, 20% glycerol, 200 g/ml poly(dI-dC)) on ice for 10 min
followed by an additional 20-min incubation on ice with 2 ng of -32P-
labeled double-stranded oligonucleotides as described below: ARE-7,
5-GCTTACTGGATCAGAGTTCACAGAT; FP-1, 5-GATTGGCT-
GGGGGCCGGGCTGCT; FP-2, 5-GGTTCCAAATTGGGGGCCG-
GGCCAG; Sp1, 5-GATCAATGGGGCGGGGCAAT; NF-I, 5-GGT-
TTTGGATTGAAGCCAATATGAG.
The reactionmixture was resolved on a 6% nondenaturing polyacryl-
amide gel (Bio-Rad) in 0.5 TBE (45 mM Tris, 45 mM boric acid, 1 mM
EDTA). The gel was dried and subjected to phosphorimaging for detec-
tion of shifted bands. For a supershift analysis, polyclonal antibodies
against NF-I, Sp1, or Sp3 (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA) were added and incubated on ice for an additional 30 min. For
competition analysis, a 200-fold molar excess of a cold probe was added
to the reactionmixture just prior to the addition of -32P-labeled probe.
Chromatin Immunoprecipitation (ChIP) Assay—The ChIP assay was
performed using the ChIP assay kit according to the manufacturer’s
protocol (Upstate Biotechnology, Inc., Lake Placid, NY). In brief, ChIP
assay was performed on HSC cultured on plastic for 7 days or NIH3T3
cells without or with transfection with NF-I, PPAR, and/or p300
expression plasmids or respective empty vectors. After a 48-h incuba-
tion, 4 106 cells/ChIP assay, were cross-linked with 1% formalde-
hyde at 37 °C for 10 min and rinsed twice with ice-cold phosphate-
buffered saline. The cells were harvested by brief centrifugation and
lysed in SDS-lysis buffer (50mmol/liter Tris-HCl, pH 8.1, 10mmol/liter
EDTA, 1% SDS, protease inhibitors). The lysates were sonicated on ice
with two pulses at 15 s each to achieve chromatin fragments ranging
between 200 and 1000 bp in size followed by centrifugation at 15,000
rpm for 10 min at 4 °C. Supernatants were collected and diluted 10-fold
in a ChIP dilution buffer (a 20-l aliquot was removed to serve as an
input sample) followed by preimmunoprecipitation clearing with 80 l
of a mixture of salmon sperm DNA/Protein A at 4 °C with rotation for
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30 min. Immunoprecipitation was carried out with 1 g of antibodies
(anti-NF-I, anti-p300, and anti-CCAAT DNA-binding factor (CBF)/
NF-Y antibodies from Santa Cruz Biotechnology) at 4 °C overnight with
rotation. After immunoprecipitation, 60 l of a mixture of salmon
sperm DNA and Protein A was added and incubated at 4 °C with rota-
tion for 30 min and followed by brief centrifugation. The precipitates
were washed twice with low salt buffer, once with high salt buffer, and
once with LiCl buffer. Then the precipitates were washed again with the
TE buffer. The immune complexes were extracted twice with 250 l of
elution buffer. The extracted complexes and the input were heated at
65 °C for 4 h after the addition of 20 l of 5 mol/liter NaCl to reverse
cross-link. Following proteinase K treatment, DNA was extracted by
phenol/chloroform solution and precipitated with 20 g of glycogen.
The recoveredDNAwas resuspended and subjected to 35 cycles of PCR
using the following primers: 1(I) procollagen promoter FP-1 region,
5-TGGACTCCTTTCCCTTCCTTTCCCTCCT-3 and 5-TGGGC-
CCCTTTTATACCATC-3; aP2 gene PPRE region, 5-TGCACATT-
TCACCCAGAGAG-3 and 5-TGTTTGGGCTGTGACACTTC-3.
The PCR products were analyzed on 1.5% agarose gel.
RESULTS
PPAR Inhibits 1(I) Procollagen mRNA Expression and Promoter
Activity—PPAR is depleted in activated HSC, whereas activation
markers including the 1(I) collagen gene are induced (15, 16). Ectopic
expression of PPAR in culture-activated HSC by an adenoviral vector
reduces the level of 1(I) procollagen mRNA by half as compared with
HSC transduced with a control GFP vector as determined by real time
PCR (Fig. 1A). Transient transfection experiment using the HSC cell
line (BSC cells) reveals that PPAR expression also decreases by 50% the
activity of a proximal 2.2-kb 1(I) procollagen promoter known to
encompass the highest basal activity in fibroblasts (19, 20) (Fig. 1B).
These results confirm the previous finding (15, 16, 18) and further sup-
port that the inhibitory effect of PPAR is at the level of the proximal
promoter.
FIGURE 1. PPAR suppresses 1(I) procollagen mRNA expression and 2.2-kb colla-
gen promoter activity. A, Taqman reverse transcription-PCR analysis shows that PPAR
expression in culture-activated HSCs by an adenoviral vector (Ad.PPAR) reduces 1(I)
procollagen mRNA level by 50%. *, p  0.05 as compared with HSC transduced with the
control GFP vector (Ad.GFP) (n  6 pairs). B, a transient transfection experiment using a
PPAR expression vector and a 2.2-kb collagen promoter-luciferase construct demon-
strates a 50% inhibition of the promoter by PPAR as compared with the cells transfected
with an empty vector (pCMX). *, p  0.05 as compared with the cells transfected with
pCMX (n  5 pairs).
FIGURE 2. PPAR suppresses the collagen pro-
moter within the 220 bp proximal promoter
region. A, a schematic diagram of four deletion
constructs within the proximal 2.2 kb 1(I) colla-
gen promoter. B, relative promoter activities of the
collagen promoter deletion constructs as com-
pared with the highest activity achieved by the
220/115 bp promoter. *, p  0.05 as compared
with the activity of pCOL3 (n  4). C, PPAR equally
inhibits each deletion construct by 50%, suggest-
ing that the primary site of the inhibitory effect of
PPAR is located within the 220 bp collagen pro-
moter region. *, p  0.05 as compared with pCMX-
transfected cells (n  4).
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A Site of the Inhibitory Effect of PPAR Is Located within the Most
Proximal 220 bp 1(I) Collagen Promoter Region—In order to assess
the region within the 2.2-kb promoter that is subjected to PPAR-me-
diated inhibition, we performed transient transfection experiments
using four deletion constructs of the promoter (Fig. 2A). The relative
activity of each of the deletion constructs was tested first by transfection
experiments in BSCs (Fig. 2B). Our results reveal that two repressor
elements: one between 2.2 and 1.8 kb and another between 1.1
and 220 bp. An enhancer element is also found between 1.8 and
1.1 kb. Of all four deletion constructs, the region proximal to220 bp
is shown to have the highest promoter activity in consistent with the
previous findings (19, 20). Co-transfection of each deletion construct
with a PPAR or empty vector reveals that PPAR inhibits all of the
deletion constructs by50% (Fig. 2C). Since the220 bp region has the
highest activity and PPAR expression equally reduces the activity of
each promoter construct, we concluded that PPAR primarily exerts its
inhibitory effectwithin the220 bpproximal region and115 bp of the
first exon. Our review of the220 bp proximal promoter sequence fails
to reveal a PPRE. Thus, PPAR must mediate the effect not via direct
repression but via its interaction with other trans-acting factor(s)
and/or cis-regulatory element(s).
Inhibition of PPAR Is Confined to DNase Footprint (FP)-1 and -2
Regions within the133 bp 1(I) Collagen Promoter—To further define
the site of PPAR-mediated inhibition, we designed and created an
additional set of deletion constructs within the most proximal 220 bp
region. This region is known to contain four protected footprints as
determined by DNase footprinting analysis of activated HSC (24) (Fig.
3A), and newly created deletions are designed to test these FP regions:
133/115 (FP-3 and FP-4 deleted but intact FP-2 and -1);120/115
(distal region of FP-2 deleted but intact FP-1); and 92/115 bp (only
proximal region of FP-1). Transient transfection experiments reveal
that the two distal footprints (FP-3 and FP-4) contribute minimally to
basal collagen promoter activity (a statistically significant change in the
promoter activity is not attained by this deletion: pCOL133) (Fig. 3B).
However, an additional deletion, including the distal half of FP-2
reduces the basal promoter activity to 50%, and a further deletionwithin
FP-1 reduces the promoter activity by another 50%. Overexpression of
PPAR expression vector results in a 50% inhibition on the pCOL133
promoter (Fig. 3C). This effect is attenuated when FP-2 is disrupted
(pCOL-120). PPAR also retains a modest inhibitory effect on the pro-
moter activity rendered only by the most proximal portion of the FP-1
(pCOL-92). However, the absolute magnitude of the activity inhibited by
PPAR accounts only for 25% of the inhibition seen with pCOL220 or
pCOL133.These results suggest thatbothFP-1andFP-2contain the sites
via which PPAR renders a major inhibitory effect on the promoter.
PPAR Inhibits NF-I Binding to FP-1 but Has No Effects on Sp1 Bind-
ing to FP-2—Since FP-1 and FP-2 are shown to be themost likely sites of
the inhibitory action of PPAR, we next investigated what trans-acting
factors bind to these regions in activated HSC. NF-I and Sp1 are shown
to comprise protein components that bind to FP-1 in NIH3T3 fibro-
blasts (19) and activated HSC (20). We used electrophoretic mobility
shift assays (EMSA) to characterize these DNA-protein interactions of
FP-1 in activated HSC. Using nuclear extracts from culture-activated
HSC and a radiolabeled oligonucleotide probe containing the FP-1
sequence, one major DNA-protein complex and another faint, higher
molecularweight band are detected. To identify proteins bound to FP-1,
supershift assays were performed using antibodies against NF-I, Sp1,
and Sp3. Although a supershifted band is not detected, NF-I antibody
clearly diminishes the major band and Sp1 antibody abrogates only the
upper, faint band. Sp3 antibody fails to affect either band (Fig. 4A). The
addition of a cold consensus NF-I binding sequence in excess, com-
pletely eliminates the protein binding to the FP-1 probe, as does the cold
FP-1 probe (Fig. 4C). The addition of a cold Sp1 consensus element in
excess eliminates the upper protein-DNA complex without affecting
the lower major band (Fig. 4C). These results demonstrate that the
lower major band of DNA-protein complex contains NF-I, and the
upper band contains Sp1 and maybe NF-I.
We also performed EMSA to determine proteins bound to the FP-2
DNA. Using nuclear extracts from activatedHSC and a FP-2 probe, two
DNA-protein bands are identified. Supershift assays reveal that Sp1
FIGURE 3. PPAR inhibits the proximal 220 bp
collagen promoter at the FP-1 and FP-2 sites. A,
a schematic diagram of deletion constructs within
the 220 bp 1(I) collagen promoter in reference
to the known four DNase footprints. B, relative
activities of the collagen promoter deletion con-
structs transfected in BSCs. *, p  0.05 as com-
pared with pCOL220 (n  5). C, co-transfection
experiments using deletion constructs and a
PPAR expression vector reveals that PPAR inhib-
its the 220 and 133 bp promoters by 45–50%,
but this inhibition is attenuated when FP-2 is dis-
rupted in pCOL-120. PPAR still suppresses
pCOL-92 containing the proximal portion of FP-1.
*, p  0.05 as compared with pCMX-transfected
cells (n  5–7).
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FIGURE 4. PPAR reduces the binding of NF-I to FP-1 but not that of Sp1 or Sp3 to FP-2. A and B, supershift assays with antibodies determine that NF-I is a major protein that binds
to FP-1, with Sp1 being a minor component. Both Sp1 and Sp3 bind to FP-2. C and D, cold probe competition confirms protein binding to FP-1 and FP-2. E, forced PPAR expression
reduces NF-I binding to FP-1 (left panel) while having no effects on Sp1 and Sp3 binding to FP-2 (middle panel). NF-I binding is confirmed by abrogation of protein-DNA complex
formation with anti-NF-I antibody (last lane of the left panel), whereas CBF binding is not evident by the lack of effect with anti-CBF antibody (Ab) (fourth lane of the left panel). PPAR
overexpression is validated by increased binding to an ARE-7 probe (a PPRE probe from the aP2 gene (right panel)). F, ChIP assay reveals CBF binding to FP-1 in NIH3T3 cells but not
in HSC (HSC1 and HSC2). IP, immunoprecipitation.
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antibody diminishes the upper band, whereas Sp3 antibody completely
abrogates the lower band (Fig. 4B). NF-I antibody has no effects. The
addition of a cold consensus Sp1 binding element in excess completely
eliminates the upper band, whereas an excess amount of unlabeled FP-2
decreases both upper and lower bands (Fig. 4D). Thus, these results
demonstrate that the upper DNA-protein complex contains Sp1, a 105/
95-kDa protein, and the lower band contains Sp3, an 80-kDa protein, in
activated HSC.
Next, we tested whether expression of PPAR affects the binding of
the nuclear proteins to FP-1 and FP-2. We performed EMSA using
FIGURE 5. PPAR inhibits NF-I-mediated collagen promoter activity and NF-I/Sp1-mediated synergistic activation of the promoter. A, a schematic drawing of the DNA
sequences of FP-1 and FP-2 of the 1(I) collagen promoter with reverse CCAAT binding sites and two identical 12-bp GC repeats. It also shows the site of mutation within the proximal
CCAAT site in FP-1. These 3-nucleotide mutations result in an almost complete loss of the pCOL133 promoter activity as compared with the wild type (WT) promoter, as shown by
transient transfection in BSCs. B, NF-I modestly but dose-dependently stimulates the collagen promoter activity in NIH3T3 cells. *, p  0.05 as compared with the control (n  4). C,
Sp1 conspicuously induces the collagen promoter activity in a dose-dependent manner. *, p  0.05 as compared with the control (n  4). D, PPAR inhibits NF-I-mediated collagen
promoter activity (*, p  0.05, n  5), and it also suppresses NF-I/Sp1 mediated synergistic induction of the collagen promoter (**, p  0.05, n  5) in NIH3T3 cells. E, the similar
inhibitory effects of PPAR are observed in BSCs.
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nuclear extracts from activated HSC infected with either Ad.PPAR or
Ad.GFP. Our results show that PPAR does not affect protein binding
to FP-2 (Fig. 4E, middle panel) but reduces the intensity of complexes
formed with the FP-1 that contain NF-I (second lane of the left panel)
(Fig. 4E). A PPAR-specific DNAbinding sequence, ARE-7, was used to
confirm increased binding of PPAR by the nuclear extracts of the
Ad.PPAR-infected cells (Fig. 4E, right panel). CBF/NF-Y binds to a
CCAAT box in the proximal murine 2(I) procollagen promoter in
NIH3T3 cells (25–27). Thus, the binding of this factor to a reverse
CCAAT site in FP-1 of 1(I) collagen promoter is possible. To test this,
we first used anti-CBF antibody for EMSAwith the FP-1 probe andHSC
nuclear extracts. As shown in the fourth lane of the left panel of Fig.
4E, this antibody does not affect the DNA-protein complex formation,
whereas anti-NF-I antibody clearly decreases it (last lane). Using the
same antibody, we also performed a ChIP assay. For this, we used both
NIH3T3 cells and HSC spontaneously activated in culture on plastic.
CBF binding to FP-1 was evident in NIH3T3 cells but not in HSC (Fig.
4F). These results demonstrate that CBF does not bind to the reverse
CCAT site in FP-1 in HSC.
NF-I Is Most Important for Proximal 1(I) Procollagen Promoter
Activity—The above data suggest that NF-I is a likely target of PPAR.
To better understand the functional importance of NF-I in the context
of the promoter of interest, 3 nucleotides in the reverse CCAAT site of
FP-1 that is shown to be critical for NF-I binding (19) were mutated
(98/96; TGG3 CAA), and the activity of the mutated pCOL133
promoter was assessed in BSCs. As shown in Fig. 5A, this mutation
almost completely abrogates the promoter activity. Because of very low
promoter activity of the mutated promoter, the effect of PPAR could
not be assessed. Nonetheless, this result demonstrates the utmost
importance of NF-I binding to the CCAAT box in FP-1 for proximal
1(I)pro-collagen promoter activity in HSC that appears to be a target
of PPAR.
PPAR Inhibits NF-I but Not Sp1-mediated Stimulation of the 133
bp Collagen Promoter—To further test the effects of PPAR on NF-I-
mediated proximal promoter activity, transient transfection experi-
ments were performed using the 133 promoter-reporter plasmid
(pCOL133) and an expression vector for NF-I, Sp1, or both in the
absence or presence of PPAR expression. We first examined the reg-
ulatory effects of NF-I and Sp1 on the promoter. For this purpose, we
used NIH3T3 fibroblasts that have been previously used to characterize
NF-I and Sp1 regulation of this specific promoter (19). A transient
transfection experiment revealed that NF-I overexpression modestly
but dose-dependently transactivated the pCOL133 promoter. A mild
1.8-fold increase in promoter activity is achieved with 300 ng of NF-I
plasmid, the maximum amount used for this experiment (Fig. 5B). On
the other hand, Sp1 overexpression markedly increases the promoter
activity as much as 350-fold with 400 ng of Sp1 (Fig. 5C). We also tested
the combined effect of NF-I and Sp1 on the collagen promoter by co-
transfecting with 100 ng each of both plasmids. This co-expression
results in a synergistic induction of the promoter activity in NIH3T3
(Fig. 5D), and the same effect is also confirmed in BSCs (Fig. 5E). We
then tested the effects of PPAR onNF-I- or Sp1-mediated activation of
the collagen promoter as well as the effect of PPAR on the synergistic
activation of this promoter by both factors. Our results show that
PPAR significantly inhibits NF-I-mediated promoter activity in
NIH3T3 and BSCs (Fig. 5, D and E). In contrast and to our surprise,
PPAR does not inhibit Sp1 transactivity toward this promoter in either
cell type (Fig. 5, D and E). In addition, PPAR significantly reduces
NF-I/Sp1 synergistic induction of the collagen promoter by in NIH3T3
and BSCs (Fig. 5, D and E). These results confirm NF-I as a primary
target for the inhibitory effect of PPAR on the proximal 1(I) collagen
promoter.
p300 Rescues the Inhibitory Effect of PPAR on NF-I-mediated Colla-
gen Promoter Activity—Our results demonstrate that PPAR inhibits
basal 1(I) procollagen promoter activity at the site upstream of 133
bp comprising overlapping NF-I and Sp1 sites. They also demonstrate
that the promoter activity stimulated byNF-I but not Sp1 is inhibited by
PPAR, and this effect is probably due to reduced NF-I binding to FP-1.
Since NF-I and PPAR share common co-activators, such as p300, and
a competition for p300 by PPAR with other transcription factors is
possible, we examined whether the inhibitory effect of PPAR on NF-I
involves p300. To address this question, we overexpressed p300 to
determine its effects on PPAR-mediated inhibition of NF-I-dependent
promoter activity. Our results show that 330 ng of the p300 expression
plasmid partially rescues NF-I from the inhibitory effect of PPAR on
each of the three collagen promoter deletion constructs tested,
pCOL133/115bp, pCOL120/115bp, and pCOL-92/115bp,
suggesting the involvement of p300 within FP-1 (Fig. 6A). In addition,
p300 dose-dependently relieves the suppression by PPAR of basal
pCOL133 promoter activity (Fig. 6B, second set of bar graphs). More
importantly, p300 dose-dependently rescues NF-I from the suppressive
effect of PPAR on the promoter (Fig. 6B, third set of bar graphs). Thus,
these results suggest that PPAR inhibits NF-I-mediated collagen pro-
moter activity at least in part via competition between these two tran-
scription factors for p300.
FIGURE 6. p300 rescues NF-I from the inhibitory effect of PPAR. A, transfection with
p300 (330 ng) partially rescues NF-I-mediated collagen promoter activity from inhibitory
regulation by PPAR. *, p  0.05 compared with the control (n  3–5) (without p300
overexpression) B, p300 dose-dependently reduces PPAR suppression of NF-I-driven
collagen promoter activity. *, p  0.05 compared with the promoter activity without NF-I
or PPAR expression but with p300 transfection at 330 ng (second bar from left) (n 
4 –5); **, p  0.05 compared with the activity by the cells transduced with NF-I and 330 ng
of p300 (eighth lane from left). IP, immunoprecipitation.
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PPAR Inhibits NF-I Binding to FP-1 inVivo via Its Suppressive Effects
on p300-stimulated NF-I-DNA Binding—We next tested whether
PPAR inhibits NF-I binding to FP-1 in vivo by the ChIP assay. First,
using antibodies against NF-I and primers flanking FP-1, we amplified
the FP-1 region that is bound with NF-I in NIH3T3 cells transduced 1)
with orwithout PPAR, 2) withNF-I with orwithout PPAR. Under the
basal condition (noNF-I overexpression), the amplified band for FP-1 in
agarose gel is tooweak to ascertain the effects of PPAR. Thus, real time
PCR using SyBer Green was performed to quantify the amplified FP-1
DNA. Using this technique, the binding of NF-I to FP-1 is shown to be
reduced by 40% by PPAR (Fig. 7A). ChIP assay also reveals NF-I bind-
ing to FP-1 under NF-I transduction is clearly inhibited by PPAR (Fig.
7B, lanes 1 and 2). These results confirm the conclusion from our in
vitrodata obtained by EMSA (Fig. 4E). Next, we examined the binding of
p300 to FP-1 by immunoprecipitating DNA with anti-p300 antibodies.
As shown in the Fig. 7B, lanes 3 and 4, the p300 binding is coordinately
suppressed by PPAR. To determine whether p300 binding to FP-1 via
NF-I is reduced, we performed a two-step ChIP assay. For this, we first
immunoprecipitated DNA with anti-NF-I antibodies, followed by PCR
and then reimmunoprecipitation with anti-p300 antibodies after a brief
treatment with dithiothreitol for the second PCR. As shown in the 5th
and 6th lanes of Fig. 7B, PPAR reduces p300 association with FP-1 via
NF-I. As a positive control for PPAR transduction, we amplified the
PPRE site for the aP2 gene after p300 immunoprecipitation. As shown in
the last two lanes of Fig. 7B, transfection with the PPAR vector expect-
edly increases the binding of p300 to the PPRE. These results may sug-
gest that NF-I binding to FP-1 is reduced by PPAR, and p300 recruit-
ment to NF-I is consequently decreased. Then why does p300
overexpression rescue the PPAR inhibitory effect on NF-I-driven pro-
moter activity (Fig. 6)? Since the effect of PPAR is mediated by sup-
pressed NF-I binding, p300 must promote NF-I binding. This notion
was tested by examining the effects of p300 onNF-I binding to FP-1 and
on PPAR-mediated inhibition of NF-I binding using the ChIP assay.
Indeed, p300 promotes the binding of NF-I to FP-1 (Fig. 7C, lane 3
versus lane 1). Further, PPAR-mediated inhibition of NF-I binding is
prevented by p300 overexpression (Fig. 7C, lane 2 versus lane 4). These
results suggest that PPAR suppresses NF-I binding to FP-1 via its inhi-
bition of p300-facilitated NF-I binding to its cognate binding site.
DISCUSSION
The present study identified a region proximal to 133 in the prox-
imal 5-flanking 1(I) procollagen promoter as the site of PPAR-me-
diated inhibition. This region encompasses two known DNase foot-
prints designated as FP-1 and FP-2 as determined using nuclear extracts
from fibroblasts (19, 20) and activated HSC (24). Both footprints have
reverse CCAAT binding sites and two identical 12-bp GC repeats (19).
The CBF is shown to bind to the most proximal CCATT site of murine
2(I) procollagen promoter in NIH3T3 cells (25–27) and of human
1(I) procollagen promoter in skin fibroblasts (28). However, the pri-
mary proteins that are shown to bind to FP-2 are Sp1 and Sp3, and NF-I
is shown to bind to the 100/96 bp CCAAT box in FP-1 in both
NIH3T3 cells and HSC (19, 24, 29). In fact, our EMSA and ChIP assays
fail to demonstrate the binding of CBF to FP-1 in HSC despite the fact
that CBF binding to the same site is evident in NIH3T3 cells (Fig. 4, E
FIGURE 7. PPAR inhibits the binding of NF-I to
FP-1 in vivo via suppression of p300-facilitated
binding of NF-I to DNA. A, basal NF-I binding to
FP-1 is reduced by PPAR. Transfection of NIH3T3
cells with a PPAR expression vector reduces the
binding of NF-I to FP-1 as determined by the ChIP
assay and Syber Green real time PCR. *, p  0.026
as compared with the cells transfected with the
empty vector pCMX. B, the cells transfected with a
NF-I expression vector show a distinct PCR band of
FP-1 after immunoprecipitation with anti-NF-I
antibody by ChIP assay (first lane), but this is
reduced by PPAR co-transfection (second lane),
demonstrating inhibition of NF-I by PPAR. P300
binding to FP-1 is also inhibited by PPAR, as
shown in the third and fourth lanes. The fifth and
sixth lanes show that PPAR inhibits p300 binding
to FP-1 via NF-I as demonstrated by the two-step
ChIP assay. The last two lanes serve to show a pos-
itive control for PPAR by demonstrating
increased p300 binding to the PPRE element in the
aP2 gene by PPAR overexpression. C, ChIP assay
with NF-I immunoprecipitation shows that p300
transduction increases NF-I binding to FP-1 (third
lane versus first lane) and completely abrogates
PPAR-mediated inhibition of NF-I binding (fourth
lane versus second lane). These ChIP assays were
repeated at least three times to determine the
reproducibility of the results.
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and F) and skin fibroblasts (28). The literature suggests PPAR causes
negative cross-coupling with Sp1 as in the case for thromboxane recep-
tor gene promoter activity in vascular smooth muscle cells (30). How-
ever, our transient transfection analysis and EMSA reveal inhibition of
neither Sp1-induced pCOL1331(I) promoter activity nor Sp1 bind-
ing to FP-2 by PPAR. Instead, both NF-I-stimulated promoter activity
and NF-I-mediated synergistic induction of Sp1 transactivity are sup-
pressed by PPAR, demonstratingNF-I as a primarymolecular target of
PPAR. To our knowledge, this is the first demonstration of negative
regulation of NF-I by PPAR. Ourmutation experiment clearly demon-
strates the utmost importance of the 100/96 CCAAT site in FP-1 to
the proximal promoter activity (Fig. 5A). Because of the very low activity
of the mutated promoter, the effect of PPAR could not be examined.
However, it seems apparent from our data that PPAR targets NF-I
interactionwith this CCAAT site. Aswe look into the underlyingmech-
anisms, PPAR is shown to inhibit NF-I binding to FP-1 as demon-
strated by EMSA and ChIP assay. More importantly, this effect is medi-
ated by suppression of p300-facilitated NF-I binding to its binding
element as revealed by a reversal by p300 of the inhibitory effects of
PPAR on both the promoter activity (Fig. 6) and NF-I binding to FP-1
(Fig. 7C).
CBP/p300 are promiscuous co-activators that contribute to tran-
scriptional activation by many transcription factors. They serve to
recruit components of the general transcriptional machinery such as
TFIID, TFIIB, and RNA polymerase. Its binding to activation domains
of transcription factors brings histone acetyltransferases close to spe-
cific nucleosomes in target gene promoters (for a review, see Ref. 31).
They also possess intrinsic acetyltransferase activity toward not only
histones but also transcription factors. As exemplified by the regulation
of p53 by p300, p300-mediated acetylation of transcription factors
increases their binding to DNA (32). Our results also demonstrate a
p300-mediated increase in NF-I binding to FP-1 of the proximal 1(I)
procollagen promoter (Fig. 7C), and this mechanism is shown to be a
target of the inhibitory action of PPAR. p300 also interacts with mul-
tiple transcription factors to facilitate a synergism for transcriptional
activation. In our study, synergism between NF-I and Sp1 is demon-
strated for pCOL133 activity, althoughNF-I alone has a modest stim-
ulatory effect (Fig. 5B). Due to the overlapping binding sites for these
two transcription factors in FP-1 and FP-2 and their proximity, this
synergism ismost likely facilitated by p300. If that were the case, PPAR
would readily reduce the synergistic activation of the collagen promoter
by its inhibitory effect on p300.As demonstrated by the deletion analysis
of the 220/115 bp promoter, the intact FP-1 and FP-2 are required
for the maximal PPAR effect (Fig. 3C). Since the Sp1 and NF-I sites in
FP-2 are disrupted in pCOL-120, the extent of inhibition is clearly atten-
uated (Figs. 3C and 5A). However, our EMSA data show the binding of
Sp1 and Sp3 but not NF-I to FP-2 (Fig. 4B). Thus, these results suggest
that the synergistic interaction of NF-I bound to FP-1 (Fig. 4A) and Sp1
bound to FP-2 is the target of PPAR, and this is disrupted in the dele-
tion construct pCOL-120. This specific aspect will need to be addressed
further by our future study.
Although our study identifies NF-I as a target for PPAR-mediated
inhibition of the proximal1(I)collagen promoter, our deletion analysis
demonstrates that PPAR still possesses a small inhibitory effect on
pCOL-92 that has the proximal NF-I site disrupted (Figs. 3C and 5A).
The absolute magnitude of this inhibition accounts only for 25% of the
inhibition observed with pCOL220 or pCOL133. Nevertheless, this
result still suggests an NF-I-independent mechanism for PPAR-medi-
ated inhibition. Indeed, the most proximal region upstream of 92 is
known to have the binding sites for other proteins. For instance, YY-1,
also known as NF-E1, binds to the element consisting of (C/t/
a)CATN(T/a)(T/g/c) located at regions40 to34 bp and35 to29
bp of the1(I) collagen promoter and up-regulates the transcription via
stabilizing the interaction between TBP and TFIID and other compo-
nents of the transcription machinery (33). YB-1, a member of the cold
shock domain protein superfamily, binds to a specific DNA sequence
(CTGATTGG) at83 to59 bp and inhibits the promoter activity due
to its ability to separateDNA strands and to prevent the binding of other
transcription factors (29). Thus, PPAR may affect the binding or tran-
scriptional regulation by these factors to render the observed inhibition
of pCOL-92 activity. Further, PPAR may also interact with other fac-
tors around the transcription start site, including the RFX family, that
serve as repressors for both collagen type I genes (34).
In summary, the present study demonstrates that PPAR reduces
NF-I-mediated 1(I) collagen promoter activity via its ability to inhibit
p300-facilitated binding of NF-I to DNA. The identification of the
molecular target for PPAR should aid in understanding the molecular
basis of the antifibrotic effects mediated by PPAR.
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